2007 - Karo Bio

A new share issue brings just over MSEK400 to the company before transaction costs.
The frst phase II study with KB2115 was finalized with positive results
KB5359, an alternative thyroid receptor stimulating compound for hyperlipidemia, was stopped due to toxicological findings
Merck stopped the development of an estrogen receptor compound after clinical phase I
Wyeth stopped the development of an LXR-receptor stimulating compound after clinical phase I
Dr Leon Rosenberg was elected Chairman of the Board succeeding Per-Olof Mårtensson
Clinical phase I was initiated for Karo Bio's compound KB3305, indicated for type 2 diabetes
Clinical phase IIb studies started with KB2115 as add on to statins
Eprotirome approved as INN-name for KB2115.